EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

TP53-mutated MDS and AML: immune dysregulation, tumor microenvironment, and emerging therapeutic strategies

Marwah M Albakri

Frontiers in Oncology · 20.08.2025 · 15

DOI: 10.3389/fonc.2025.1655486 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Oncology, online erschienen am 20.08.2025. Verfasst von Marwah M Albakri. Beteiligte Einrichtung: Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Taibah University, Madinah, Saudi Arabia. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 105 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

TP53 mutations drive oncogenesis and therapeutic resistance in myelodysplastic syndromes (MDSs) and acute myeloid leukemia (AML), impairing p53-regulated functions such as apoptosis, immune surveillance, and genomic stability, leading to immune evasion and metabolic reprogramming. The tumor microenvironment in TP53 -mutated MDS and AML fosters leukemic progression through cytokine dysregulation, altered metabolism, and immune suppression. Current therapies, including chemotherapy and hypomethylating agents, offer limited efficacy, resulting in poor overall survival rates for these high-risk patients. However, novel therapeutic approaches provide promising avenues, including MDM2 inhibitors, p53-reactivating agents, pathway-targeted inhibitors (Hedgehog, Wnt, NF-κB), immune modulation (checkpoint inhibitors, CAR-T therapy), metabolic interventions (fatty acid metabolism, glycolysis), and gene-editing technologies (CRISPR/Cas9, base editing). This review explores the mechanisms of immune dysfunction in TP53 -mutated MDS and AML while highlighting emerging therapeutic strategies, emphasizing the integration of targeted, metabolic, and immune-modulating therapies as a transformative approach to improve patient outcomes.

Schlagwörter

Stichwörter der Autor:innen

TP53 mutationacute myeloid leukemia (AML)immune evasionmyelodysplastic syndromes (MDS)targeted therapiestumor microenvironment

Autor:innen und Institutionen

  • Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Taibah University, Madinah, Saudi Arabia.
  • Health and Life Research Center, Taibah University, Madinah, Saudi Arabia.

Zitieren

APA

Albakri, M. M. (2025). TP53-mutated MDS and AML: immune dysregulation, tumor microenvironment, and emerging therapeutic strategies. Frontiers in Oncology, 15. https://doi.org/10.3389/fonc.2025.1655486

Vancouver

Albakri MM. TP53-mutated MDS and AML: immune dysregulation, tumor microenvironment, and emerging therapeutic strategies. Frontiers in Oncology. 2025;15. doi:10.3389/fonc.2025.1655486

BibTeX
@article{Albakri2025,
  author = {Albakri, Marwah M},
  title = {TP53-mutated MDS and AML: immune dysregulation, tumor microenvironment, and emerging therapeutic strategies},
  journal = {Frontiers in Oncology},
  year = {2025},
  volume = {15},
  doi = {10.3389/fonc.2025.1655486}
}
Kostenlos starten →